Studies do not link heart risk to bone drugs: FDA
WASHINGTON (Reuters) - A review of clinical trial data from four drugmakers shows no overall risk of heart problems in patients taking drugs to treat osteoporosis, the U.S. Food and Drug Administration said on Wednesday.
The agency reviewed studies on Merck & Co’s Fosamax, Roche’s Boniva, Novartis AG’s Reclast and Procter and Gamble Co’s Actonel and found heart rhythm problems were “rare within each study, with most studies containing two or fewer events.”
Still, the FDA said it was considering whether conducting further studies to investigate the risk were feasible.
The agency released its findings on its website here
(Reporting by Susan Heavey; Editing by Maureen Bavdek)
--------------------------------------------------------------------------------------------Related Posts:
By Gene Emery BOSTON (Reuters) - Merck’s popular osteoporosis drug Fosamax and other similar drugs may carry a risk for esophageal cancer, a Food and Drug Administration official said on Wednesday. Diane Wysowski of the FDA’s division of drug risk asessment said researchers should check into potential links between so called bisphosphonate drugs and cancer. In a letter
Full Post: Esophageal cancer linked to osteoporosis drugs
--------------------------------------------------------------------------------------------
NEW YORK (Reuters Health) - Patients with heart rhythm disturbances who have an implantable heart defibrillator are particularly vulnerable to air pollution, a Swedish study indicates. In patients with these devices, known as implantable cardioverter defibrillators, or ICDs, exposure to air pollution may rapidly (within 2 hours) prompt ventricular arrhythmia — a potentially life-threatening condition in
Full Post: Air pollution may prompt abnormal heart rhythm
--------------------------------------------------------------------------------------------
NEW YORK (Reuters) - New data do not signal any heart risks with Takeda Pharmaceutical Co Ltd’s experimental drug to treat acid build-up in patients with gout, a top U.S. Food and Drug Administration official said in a document released on Thursday. Takeda is seeking U.S. approval to sell its drug febuxostat for chronic gout patients
Full Post: No heart risk seen with Takeda gout drug: FDA
--------------------------------------------------------------------------------------------
By Lisa Richwine WASHINGTON (Reuters) - U.S. regulators have received reports of serious and unexpected problems in people treated with wrinkle-fighting injections known as dermal fillers, Food and Drug Administration staff said in a report released on Friday. The problems included facial palsy, disfigurement and “rare but life-threatening events such as severe allergic reactions and anaphylactic shock,”
Full Post: Problems reported with wrinkle fillers in U.S.
--------------------------------------------------------------------------------------------
VANCOUVER, British Columbia (Reuters) - Canadian health officials urged parents on Thursday not to give over-the-counter cold medicines to children under the age of six, citing concern over misuse and overdoses. The federal health agency, Health Canada, which had earlier this year recommended the medicines not be given to children less than two years old, said
Full Post: Canada sets new limits on cold medicine for children